
Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Your AI-Trained Oncology Knowledge Connection!


Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer.










Published: November 20th 2020 | Updated:

Published: July 29th 2023 | Updated:

Published: October 20th 2020 | Updated:

Published: October 20th 2020 | Updated:

Published: October 20th 2020 | Updated:

Published: October 20th 2020 | Updated: